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Background: Induction of cell apoptosis and regulation of cell cycle are very attractive for treatments of tumors
including ovarian carcinoma. Flavopiridol is a potent small molecular cyclin-dependent kinase(cdk) inhibitor, but its
antitumor efficacy is not satisfied yet. Caspase-3 play a major role in the transduction of apoptotic signals and the
execution of apoptosis in mammalian cells. We have successfully constructed the recombinant adenovirues
AdHTVP2G5-rev-casp3 containing autocatalytic caspase-3 (rev-caspase-3) driven by amplified hTERT promoter
system (TSTA-hTERTp). In this study, we applied it with flavopiridol to investigate their antitumor effect on ovarian
cancer in vitro and in vivo.
Methods: Cell viabilities were determined using Cell Counting Kit 8 and flow cytometry. RT-PCR and immunoblotting
assays were used to detect cellular apoptotic activities. Tumor growth and survival of mice bearing tumors were studied.
Results: Flavopiridol or AdHTVP2G5-rev-casp3 at low dosage alone was mildly cytotoxic in vitro with a viability rate of
86.5 ± 4.7% for 300 nM flavopiridol and 88.9 ± 5.4% for AdHTVP2G5-rev-casp3 (MOI 20). By contrast, significant synergism
of their sequential combination was observed, and the treatment of AdHTVP2G5-rev-casp3 (MOI 20) infection for 72 h,
followed by flavopiridol (300 nM) for 48 h, can result in the most synergistic cell death, with cell survival rate and
apoptotic rate of 11.6% and 69.7%, respectively. The sequential combination showed synergistic tumor suppression rate
of 77.8%, which was significantly higher than that of AdHTVP2G5-rev-casp3 (33.6%) or flavopiridol (40.1%) alone. The
mean survival of mice treated with the combination was 286 ± 8 d, which was synergistically longer than that of mice
treated with AdHTVP2G5-rev-casp3 (141 ± 14d), flavopiridol (134 ± 10 d) or controls (106 ± 11 d) (P < 0.01).
Conclusions: The sequential combination of rev-caspase-3 and flavopiridol result in significant synergistic cell killing
effects, significant tumor growth suppression and extended survival of mice bearing OVCAR3 cells. The combination
should be further explored as a potential clinically useful regimen against ovarian cancer.
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Deregulated cyclin-dependent kinase (cdk) activity is a hall-
mark of human cancer. Ectopic expression of cdk inhibitors
in tumor cell lines usually results in cell cycle arrest in G1
or G2 or both, and this has translated into therapeutic
benefit in xenograft models with slowed tumor growth and
improved host survival [1]. Flavopiridol is a small molecule
potent inhibitor of cdks, which is structurally related to a
compound derived from the plant Dysoxylumm binectari-
ferum. It strongly inhibits cdk1, cdk2, cdk4, and cdk7 and
exerts cytostatic or cytotoxic activities against various hu-
man cancer cell lines. It also inhibits various kinases such
as protein kinase A and C and epidermal growth factor-
receptor tyrosine kinase at micromolar concentrations. It
also broadly suppressed the transcription of genes, includ-
ing cyclin D1, and binds to DNA [1-4]. To date, the results
from phase II clinical trials of flavopiridol as a single agent
are unsatisfactory [5]. Combination therapy of flavopiridol
with other drugs have been attempted to improve the effi-
cacy against various tumor types [6,7].
Caspase-3 plays a major role in the transduction of the
apoptotic signal and execution of apoptosis in mammalian
cells. There has been interest in using the pro-apoptotic
caspase-3 gene for therapy against cancer. Yamabe et al.
showed that caspase-3 transgene therapy in combination
with an additional death-inducing therapeutic agent could
be effective against various tumor types [8]. Shinoura et al.
also showed that caspase-3 gene therapy required a pro-
apoptotic signal to induce effective tumor cell killing [9].
Our group constructed constitutively active recombinant
caspase-3 precursors (rev-caspase-3) that were capable of
auto-processing and inducing significant apoptosis in vivo
independent of the upstream caspases [10]. We also gener-
ate an amplified hTERT promoter system for efficient tran-
scriptional targeting of active caspase-3 by using a two-step
transcription amplification (TSTA) system. Our data have
demonstrated a potent, hTERT-restricted apoptosis which is
induced by adenovirus-mediated active caspase-3 gene driven
by hTERTp-TSTA system in human ovarian cancer cells.
We hypothesized that adenovirus mediated delivery of
constitutively active recombinant caspase-3 precursors to
tumor cells in combination with flavopiridol may exhibit
enhanced cytotoxicities against tumor cells when com-
pared with either agent used alone. In the current study,
we investigated the effect of the combination of flavopiri-
dol and recombinant caspase-3 on OVCAR3 cells in vitro
and in mouse xenograft model. We observed a very potent
induction of apoptosis by the sequential combination treat-
ment of these agents both at low doses in the cancer cells.
Materials and methods
Cell culture and drug preparation
Human ovarian adenocarcinoma cell line OVCAR3
(Nanjing Biotechnology Development Co., Ltd.) wasmaintained in RPMI1640 (Gibco, Grand Island, NY) sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS) at 37°C with 5% CO2 in air. Flavopiridol, which was
kindly provided by Professor Geoffrey I. Shapiro at the US
National Cancer Institute, was prepared in dimethyl sulf-
oxide (DMSO) at a working concentration of 25 mM and
stored at - 20°C and was diluted in fresh medium before
use.
Adenoviral vectors
AdHTVP2G5-rev-casp3, a recombinant adenoviral vec-
tor expressing rev-caspase-3 driven by the hTERTp-
TSTA system, was constructed by our laboratory. Details
of the recombinant vector are available upon request.
Cell viability assays
OVCAR3 cells were seeded at a density of 1.7 × 104 cells
per well on 96-well plates and after an overnight incuba-
tion were treated with flavopiridol and/or AdHTVP2G5-
rev-casp3 at the indicated doses. Cell viability was assessed
using the Dojindo Cell Counting Kit-8 (Dojindo Labora-
tories, Gaithersburg, MD) according to the supplier’s rec-
ommendations. Absorbance was read at 450 nm and cell
viability was expressed as the percentage of viable cells
relative to untreated cells. All experiments were performed
in triplicate and at least three times independently.
Cell-cycle analysis
Treated OVCAR3 cells were washed once with phosphate
buffered saline (PBS), trypsinized, and washed again in PBS
with 2% FBS and then fixed in ice-cold ethanol for at least
1 h at −20°C. Then the cells were stained with propidium
iodide (30 μg/ml) and treated with RNase (0.6 mg/ml) in
PBS plus 0.5% (v/v) Tween20 and 2% FBS. Stained cells
were analyzed on a FACS Calibur flow cytometer (BD
Bioscience) using the Cellquest software, and the ModFit
program (Verity Software House Inc, Topsham, ME) was
used to analyze the cell-cycle profiles.
Real time PCR
Total cellular RNA was isolated using the Trizol Reagent
(Invitrogen, Carlsbad, CA). First-strand cDNA synthesis
was carried out using reverse transcriptase (Invitrogen) by
incubation at 25°C for 10 min, 37°C for 60 min and 95°C
for 5 min. The sequences of primers used for real-time
PCR were as follows: cyclin D: 5’-GAGGTCTGCGAG
GAACAGAAGT-3’ (sense) and 5’-TTGAGCTTGTTC
ACCAGGAGC-3’ (anti-sense); active caspase-3: 5’-CC
ATGCTGAAACAGTATGCCG-3’ (sense) and 5’-TTCCA
GAGTCCATTGATTCGCT-3’ (anti-sense); GAPDH: 5’-
ACCACAGTCCATGCCATCAC-3’ (sense) and 5’-TCC
ACCACCCTGTTGCTGTA-3 (anti-sense). Amplification
was performed in a 25-μL reaction containing 2 μL sample
cDNA, 0.4 × TaqMan Universal PCR Master Mix (Applied
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probe. The PCR was run at 94°C for 2 min followed by
40 cycles of 94°C for 5 s, 62°C for 10s and 60°C for 30s.
Amplification was performed according to the manufac-
turer’s specifications.
Immunoblotting studies
Cell lysates were prepared as previously described. Im-
munoblotting procedure was carried out as depicted earlier
[11]. The following antibody was used for immunoblotting:
anti-PARP antibody and anti-caspase-3 antibody (Cell
Signaling Technology, Danvers, MA).
Xenograft studies
The study protocol was approved by the local institution
review board at the authors’ affiliated institution. Female
mice, 4 to 6 weeks old and weighing 16 to 20 g (Animal
Research Institution of Chinese Academy of Medical Sci-
ences, Beijing, China), were used for the experiment. All
animals were cared for according to the Guidelines for the
Care and Use of Laboratory Animals and the institutional
guidelines of Chinese Academy of Medical Sciences. For
the subcutaneous tumor model, 1 × 107 OVCAR3 cells in
0.2 ml PBS were inoculated subcutaneously into the dorsal
flank of nude mice. When the tumor reached a volume of
~150 mm3, these mice received intratumoral injections of
PBS, AdHTVP2G5-rev-casp3 (7 × 108 tissue culture infec-
tious dose 50 (TCID50)/tumor), flavopiridol (10 mg/kg)
and the sequential combination treatment in which flavo-
piridol (5 mg/kg) was injected 72 h after treatment with
AdHTVP2G5-rev-casp3 (7 × 108 TCID50/tumor). Three
intratumoral injections were given every 10 d and 5 mice
from each group were followed up once per three days to
measure tumor size by calipers. Tumor volumes were
calculated using the formula a × b2 × 0.5, where a and b
represent the larger and smaller diameters, respectively.
Mice were sacrificed according to the institutional guide-
lines when the tumor reached 2000 mm3 in volume.
For the peritoneal tumor model, 1 × 107 OVCAR3 cells
in 0.5 ml PBS were injected intraperitoneally into the nude
mice. Subsequently, mice were weighed once every two
days. Twenty-one days after inoculation, the mice received
intra peritoneal injections of PBS, AdHTVP2G5-rev-casp3
(7 × 108 TCID50/tumor), flavopiridol (10 mg/kg) and the
sequential combination treatment in which flavopiridol
(5 mg/kg) was injected 72 h after treatment with
AdHTVP2G5-rev-casp3 (7 × 108 TCID50/tumor). Three
intraperitoneal injections were given every 10 days. Sur-
vival was defined as the study endpoint. Histopathological
changes in the liver, spleen, intestine, lung, kidney, ovary,
pancreas and heart were examined and serum contents of
alanine transaminase (ALT) and aspartate transaminase
(AST) were performed as described previously [12]. Blood
samples were collected via the tail vein on d 1 and 14 tomonitor liver damage, and, specifically, the serum levels of
AST and ALT in each group.
Statistical analysis
Statistical differences among the treatment groups were
assessed by ANOVA using SPSS11.5 software program.
A value P < 0.05 was considered significant. Additionally,
the survival data was summarized and plotted using the
Kaplan-Meier method, and survival curves were com-
pared using the log-rank test.
Results
Sequential combination treatment of flavopiridol and
AdHTVP2G5-rev-casp3 suppresses the survival of OVCAR3
cells in vitro
We treated human ovarian adenocarcinoma cells OVCAR3
with 300 nM flavopiridol for 24 hs and then examined the
viability of these cells using the CCK-8 method. We found
that flavopiridol was only mildly cytotoxic with a viability
rate of 86.5 ± 4.7%. Examination by flow cytometry of the
sub-G1 population also found only a modest increase in
the percentage of cells in the sub-G1 peak (10.3 ± 3.2% for
300 nM flavopiridol vs. 1.1 ± 2.9% for controls). Addition-
ally, we infected OVCAR3 cells with AdHTVP2G5-rev-
casp3 at an multiplicity of infection (MOI) of 5 to 40 for
72 h. Viability assays using the CCK-8 method showed that
AdHTVP2G5-rev-casp3 caused a dose dependent suppres-
sion of the survival of OVCAR3 cells with 97.1 ± 4.8% of
the cells viable at an MOI of 5 and 61.3 ± 8.1% of the cells
viable at an MOI of 40 (Figure 1A). Flow cytometry further
indicated a dose-dependent increase in the percentage of
OVCAR3 cells undergoing apoptosis with an apoptotic
rate of 3.1 ± 1.5% at an MOI of 5 and 21.8 ± 4.3% at an
MOI of 40 (Figure 1B).
We next examined the effect of sequential combination
treatment of AdHTVP2G5-rev-casp3 and flavopiridol on
the proliferation of OVCAR3 cells. We treated OVCAR3
cells first with AdHTVP2G5-rev-casp3 at an MOI of 5 to
40 for 72 h followed by 300 nM for 48 h. Viability assays
using the CCK-8 method showed that AdHTVP2G5-rev-
casp3 at an MOI of 5 to 40 in combination with flavo-
piridol significantly suppressed the survival of OVCAR3
cells with a viability rate of 39.6 ± 7.9% at an MOI of 5 and
5.8 ± 4.1% at an MOI of 40 (Figure 1A), which was mark-
edly lower than that of OVCAR3 cells treated with
AdHTVP2G5-rev-casp3 and flavopiridol alone (P < 0.05).
Flow cytometry additionally showed that the sub-G1 frac-
tion increased to 43.4 ± 6.9% to 71.9 ± 7.0% in OVCAR3
cells treated with AdHTVP2G5-rev-casp3 at an MOI of
5 to 40 in combination with flavopiridol, which was
markedly higher than that of OVCAR3 cells treated
with AdHTVP2G5-rev-casp3 and flavopiridol alone
(P < 0.05) (Figure 1B). These findings demonstrated that
AdHTVP2G5-rev-casp3 and flavopiridol synergistically
AB
C
Figure 1 Treatment with AdHTVP2G5-rev-casp3 sensitizes OVCAR3 cells to subsequent flavopiridol exposure. A and B: Cell viability and
apoptosis determined by CCK-8 assay and flow cytometry. OVCAR3 cells were infected by AdHTVP2G5-rev-casp3 alone at different MOIs as
indicated, or 72 hs later, followed by flavopiridol (300 nM) for 48 hs. The results demonstrate the combination treatment can produce significant
synergism of cell-killing effect using AdHTVP2G5-rev-casp3 at MOI of 5 ~ 40. The standard deviation for triplicate wells was less than 10%. C: Cells
were infected with AdHTVP2G5-rev-casp3(MOI = 20) alone for 72 hs(rAd72 h), or 300 nM flavopiridol alone for 24 hs or 48 hs(300 F 24 h and 300 F 48 h,
respectively). Alternatively, cells were infected with AdHTVP2G5-rev-casp3(MOI = 20) for 0 ~ 72 hs, followed by 300 nM flavopiridol for 48 hs (20 rAd
0 ~ 72 h + 300 F 48 h) or AdHTVP2G5-rev-casp3(MOI = 20) for 72 hs, followed by 300 nM flavopiridol for 24 hs(20 rAd 72 h + 300 F 24 h). Results
demonstrate the sequential dependence of the AdHTVP2G5-rev-casp3/flavopiridol combination. Administration of the sequential 20 rAd 72 h + 300 F
48 h combination was more effective than other combinations.
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nificant apoptotic activities in these cells.
Moreover, the extent of cell death by the sequential
combination was time dependent. We observed the cell
survival rates when cells were infected by AdHTVP2G5-
rev-casp3(MOI = 20), and then 0 ~ 72 h later, followed
by flavopiridol (300 nM) for 24 ~ 48 hs. The results
showed that the cell-killing synergism of them was the
most potent when flavopiridol was added into cells at
72 h after the viral infection and lasted for 48 hs, in
which the survival rate of OVCAR3 cells was 11.6 ±
4.6%,and the apoptosis rate was 69.7 ± 7.4% (Figure 1C).Sequential combination treatment of flavopiridol and
AdHTVP2G5-rev-casp3 causes significantly enhanced
apoptotic activities in OVCAR3 cells
We further examined the levels of active caspase-3 in
OVCAR3 cells treated with AdHTVP2G5-rev-casp3
(MOI = 20), 300 nM flavopiridol or their sequential com-
bination by RT-PCR. We found that the mRNA tran-
script levels of active caspase-3 increased 55.82% in cells
treated with AdHTVP2G5-rev-casp3 (3.95 ± 1.92) com-
pared with controls (2.51 ± 1.56) (P < 0.05) while no ap-
parent difference was found between the control cells
and cells treated with flavopiridol (2.63 ± 1.15). The
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OVCAR3 cells subjected to the sequential combination
treatment with AdHTVP2G5-rev-casp3 and flavopiridol
(5.74 ± 2.43) than those of controls or cells treated with
flavopiridol alone (P < 0.05 in both). Our immunoblotting
analysis further revealed that the sequential combination
treatment with AdHTVP2G5-rev-casp3 and flavopiridol
caused significant increase in the levels of cleaved caspase-
3 (p17) and cleaved PARP (p85) fragment (Figure 2).
These findings further confirmed that AdHTVP2G5-rev-
casp3 and flavopiridol caused significantly enhanced apop-
totic activities in OVCAR3 cells.
AdHTVP2G5-rev-casp3 of low dose causes accumulation
of OVCAR3 cells in the S-phase and significantly enhances
apoptosis induced by flavopiridol
Flow cytometric analysis further showed that AdHTVP2G5-
rev-casp3 (MOI = 10) caused a significant delay in S-phase
progression with 130.6% increase in the percentage of
OVCAR3 cells in the S-phase after the infection for 72 hs
(67.8 ± 6.8% for AdHTVP2G5-rev-casp3 vs. 29.4 ± 5.2%
for controls). Moreover, release into flavopiridol at 72 h
after the viral infection by 48 h results in abrupt cell death
of the majority of the population, compared with release
into DMSO, in which cells continue to cycle (cell apop-
tosis rate of 60.1 ± 5.3% for the sequential combination of
AdHTVP2G5-rev-casp3 and flavopiridol vs. 1.1 ± 2.9% for
control). However, the cell cycle profile is not appreciably
changed 36 h after cells were infected with AdHTVP2G5-
rev-casp3(MOI = 10). Release into flavopiridol at this
time point induces only a small amount of apoptosis
compared with release into DMSO(cell apoptosis rate of
9.9 ± 4.6% vs. 2.5 ± 1.8%)( Table 1, Figure 3A-3H).
We examined the levels of cyclin D in OVCAR3 cells
treated with AdHTVP2G5-rev-casp3, flavopiridol or theirFigure 2 Western blot analysis of apoptosis-related proteins. The cells w
flavopiridol. Total protein extract of the cells was obtained, and Western blot a
untreated control; Lane 2, AdHTVP2G5-rev-casp3(MOI = 20) for 48 hs; Lane 3, 3
48hs, followed by 300 nM flavopiridol. Western blot shown are representativesequential combination by RT-PCR. We found no signifi-
cant difference in cyclin D mRNA levels between control
cells (0.69 ± 0.37) and those treated with AdHTVP2G5-
rev-casp3 (0.72 ± 0.53). However, flavopiridol (300 nM)
caused a marked reduction in the mRNA transcript levels
of cyclin D (0.35 ± 0.31) compared with controls (P < 0.01).
In addition, cyclin D mRNA levels were significantly lower
in cells treated with AdHTVP2G5-rev-casp3 (MOI 20) in
combination with flavopiridol (0.47 ± 0.39) than those of
controls (P < 0.01).
Sequential combination treatment of AdHTVP2G5-rev-
casp3 with flavopiridol suppresses tumor growth and ex-
tends the survival of tumor xenograft-bearing mice
To evaluate the in vivo efficacy of the sequential combin-
ation treatment of AdHTVP2G5-rev-casp3 with flavopiri-
dol, we established mouse xenograft model by inoculating
OVCAR3 cells subcutaneously in the nude mice and
treated the mice with AdHTVP2G5-rev-casp3 and/or
flavopiridol. Immunohistochemistry has confirmed the
OVCAR3 xenograft. Fifty-three days after treatment, the
tumor volume was 1458 ± 326, 1317 ± 295 and 487 ±
63 mm3 in mice bearing OVCAR3 xenograft treated with
AdHTVP2G5-rev-casp3, flavopiridol and the sequential
combination of AdHTVP2G5-rev-casp3 and flavopiridol,
respectively. All treatments showed significant suppression
of tumor growth at the end point of the study, with the
tumor growth suppression rate of 33.6%, 40.1% and 77.8%
for AdHTVP2G5-rev-casp3, flavopiridol and their com-
bination, respectively (P < 0.05), as shown in Figure 4a.
Moreover, we observed the synergism against xenograft
growth between AdHTVP2G5-rev-casp3 and flavopiridol
in vivo.
We next tested the effects of AdHTVP2G5-rev-casp3
and/or flavopiridol in vivo in an abdominally spreadere plated in 100-mm plates and treated with AdHTVP2G5-rev-casp3/
nalysis was performed as described in “Materials and methods.” Lane 1,
00 nM flavopiridol for 24 hs;Lane 4, AdHTVP2G5-rev-casp3(MOI = 20) for
of three independent experiments.
Table 1 The apoptosis and cell cycle distributon of OVCAR3 cells after the sequential combination treatment of






Negative control 1.1 ± 2.9 51.7 ± 3.4 29.4 ± 5.2 18.9 ± 1.9
Flavopiridol(300nM) 24 hs 10.0 ± 3.2 63.8 ± 3.9 14.3 ± 1.5 21.9 ± 2.6
Ad. 36 hs 2.1 ± 0.3 52.6 ± 4.8 20.3 ± 2.7 27.1 ± 2.8
Ad.36 hs + DMSO 48 hs 2.5 ± 1.8 50.2 ± 3.8 21.9 ± 3.0 28.9 ± 3.1
Ad. 36 hs + Flavopiridol 48 hs 9.9 ± 4.6 48.5 ± 4.0 23.4 ± 3.1 28.1 ± 3.1
Ad.72 hs 4.8 ± 0.6 12.9 ± 2.1 67.8 ± 6.8* 19.3 ± 1.9
Ad.72 hs + DMSO 48 hs 5.2 ± 0.9 16.1 ± 2.6 62.5 ± 4.3 21.4 ± 2.2
Ad. 72 hs + Flavopiridol 48 hs 60.1 ± 5.3** 51.8 ± 3.8 22.3 ± 3.0 25.9 ± 3.1
*P < 0.01, **P < 0.01.
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group was recorded. Kaplan-Meier analysis indicated
that AdHTVP2G5-rev-casp3, flavopiridol or sequential
combination of AdHTVP2G5-rev-casp3 and flavopiridol












Figure 3 Flow cytometric analysis in OVCAR3 cells. A-D: Cells were trea
DMSO or 300 nM flavopiridol for 48 hs. E-H, After treatment with AdHTVP2
And then cells were subsequently treated with DMSO or 300 nM flavopirid
results in death of the majority of the cell population, inferred from the larintraperitoneal inoculation of OVCAR3 cells compared
with control mice treated with PBS (P < 0.01) (Figure 4b).
Furthermore, sequential combination of AdHTVP2G5-
rev-casp3 and flavopiridol significantly prolonged sur-










ted with AdHTVP2G5-rev-casp3(MOI = 10), 36 h later, followed by
G5-rev-casp3(MOI = 10), 72 h later, cells were accumulated in S-phase.
ol for 48 hs. Treatment with flavopiridol after recruitment to S-phase
ge percentage of cells with sub-G1 DNA content.
AB
Figure 4 In vivo antitumor activity. A: Subcutaneous tumors derived from OVCAR3 cells were treated as shown. Tumor volumes were
monitored over time (days) after inoculation of tumor cells. Values represent the mean of 5 mice per group. B: 1:PBS, 2: flavopiridol (10 mg/kg),
3: AdHTVP2G5-rev-casp3 (7 × 108 TCID50/mouse), 4: AdHTVP2G5-rev-casp3(7 × 108 TCID50/mouse) + flavopiridol(5 mg/kg). Survival curves and
mean survival durations for animals bearing abdominally spread OVCAR3 tumors. The animals received three treatments using PBS, flavopiridol,
AdHTVP2G5-rev-casp3 or flavopiridol + AdHTVP2G5-rev-casp3 as described in the text. Survival was then monitored: the survival duration in
animals receiving treatment using AdHTVP2G5-rev-casp3, flavopiridol or flavopiridol + AdHTVP2G5-rev-casp3 were significantly differently from
those in the mice that received treatment using controls (P < 0.01). In addition, synergisms of AdHTVP2G5-rev-casp3 and flavopiridol were
observed, and significantly prolonged survival can be achieved using combined AdHTVP2-G5-rev-casp3 and flavopiridol therapy without an
increase in doses(P < 0.05).
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mean survival of mice treated with sequential combin-
ation of AdHTVP2G5-rev-casp3 and flavopiridol was
286 ± 8 d with a median survival of 283 ± 7 d. This was
significantly longer than the mean survival of mice
treated with AdHTVP2G5-rev-casp3 (141 ± 14 d), flavo-
piridol (134 ± 10 d) or PBS (106 ± 11 d) (P < 0.01). Syner-
gistic actions of AdHTVP2G5-rev-casp3 and flavopiridol
were observed in extending the survival of the tumor-
bearing mice with the mean and median survival of
these mice almost doubled compared with mice treated
with AdHTVP2G5-rev-casp3 or flavopiridol alone.Toxicity after intraperitoneal drug administration
We also examined the toxicity profiles of intraperitoneal
administration of AdHTVP2G5-rev-casp3 and/or flavo-
piridol. We measured serum ALT and AST levels and
found that they were only slightly elevated in mice re-
ceiving sequential combination of AdHTVP2G5-rev-
casp3 and flavopiridol at low doses. The AST and ALT
levels were significantly lower in mice receiving sequen-
tial combination of AdHTVP2G5-rev-casp3 and flavo-
piridol 1d after treatment than that in mice receiving
10 mg/kg flavopiridol (88.1 ± 7.8 vs. 289.3 ± 15.7, 91.5 ±
9.4 vs. 548.1 ± 42.9,respectively, P < 0.01 in both). On day
Song et al. Journal of Ovarian Research  (2014) 7:121 Page 8 of 1014, no significant difference in AST or ALT was seen
among the groups (Figure 5a and 5b). We also examined
the histopathological changes in the liver, spleen, intes-
tine, lungs, kidneys, ovary and heart and we found no
obvious lesions in mice receiving sequential combination
of AdHTVP2G5-rev-casp3 and flavopiridol.
Discussion
Cdk inhibitor flavopiridol has been demonstrated to
exert potent antitumor activities in various preclinical
tumor models [12,13]. It is possible that cdk inhibition
by flavopiridol is primarily cytostatic in the majority of
solid tumors not typically predisposed to apoptotic re-
sponses. In the study, we also found that flavopiridol
was only moderately cytotoxic against human ovarian
carcinoma cells in vitro but it demonstrated signifi-
cantly improved survival of tumor-bearing mice com-
pared with controls at 106 ± 11d post treatment. This
survival advantage, however, disappeared at 134 ± 10 d
post treatment, suggesting the modest activities of the
agent. By contrast, the sequential combination treat-
ment with AdHTVP2G5-rev-casp3 and flavopiridol not
only showed synergistically enhanced cytotoxicities
against human ovarian carcinoma cells in vitro but also
significantly prolonged the survival of tumor-bearing
mice with a median survival of 283 ± 7 d.A
B
Figure 5 Serum AST and ALT levels in abdominally spread tumor mo
AST and ALT levels: Serum samples were collected before treatment startedIn our study, significant synergism with flavopiridol was
observed when cells were treated with AdHTVP2G5-rev-
casp3 at low doses. There is a very strong increase in cell
death and the presence of a pronounced sub-G1 fraction,
when the cells were infected by AdHTVP2G5-rev-casp3
at MOI of 5 ~ 20, followed by flavopiridol for 48 hs at 300
nM. The sub-G1 fraction increased to 43.4 ~ 71.9% and
the cell survival rates decreased to 39.6% ~ 5.8%, accom-
panied with a significant decrease in S-phase content in
the sequential combination treatment, compared with ei-
ther flavopiridol or AdHTVP2G5-rev-casp3 treatment at
drug concentrations above that alone produce almost no
cell death. The cell-killing synergism of them was the most
potent when the cells were infected by AdHTVP2G5-rev-
casp3 at MOI of 20. However, the synergism became weak
with the MOIs increased to more than 40, at which dose
AdHTVP2G5-rev-casp3 treatment alone began to induce
significant cell apoptosis with no recruitment of cells to S-
phase. No significant synergism was observed when cells
were treated at MOI of 70 ~ 100.
Moreover, the extent of cell death by the sequential
combination was time dependent. We observed the cell
survival rates when cells were infected by AdHTVP2G5-
rev-casp3(MOI = 20), and then 0 ~ 72 h later, followed by
flavopiridol (300 nM) for 24 ~ 48 hs. The results showed
that the cell-killing synergism of them was the mostdel mice after intraperitoneal drug administration. A and B: Serum
(day0), and one(day1) and 14 days(day14) after the last treatment.
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the viral infection and lasted for 48 hs.
Utilization of hTERT promoter that is predominantly
active in tumor cells would be an effective system to re-
strict rev-caspase-3 expression [14-16]. However, in most
cancer cells, the hTERT promoter activity is more than
10-fold lower than that of the CMV promoter, and is too
weak to achieve sufficient transgene expression. It has
been shown that transgene expression from a tumor-
specific promoter can be augmented by using TSTA
system [17-19]. In the present study, we constructed the
TSTA system using the hTERT promoter to drive a
chimeric transcription factor consisting of the powerful
herpes simplex virus VP16 transcriptional activation
domain fused to the DNA-binding domain of the yeast
protein GAL4, which then binds to the GAL4-binding
sites upstream of a minimal promoter to activate rev-
caspase-3 gene expression. Our studies showed that the
TSTA system elevated the activity of the hTERTp up to
a 200-fold in human ovarian cancer cell lines (data
available upon request). Our in vitro and in vivo data
about AdHTVP2G5-rev-casp3 demonstrated a strong,
hTERT-restricted antitumor activity with significant
reduction in liver toxicity.
It has been shown that cell lines can be sensitized to
flavopiridol after recruitment to the S-phase. Apart from
rev-caspase-3, treatment with non-cytotoxic concentrations
of chemotherapeutic agents, including gemcitabine,
cisplatin, and topoisomerase I and II inhibitors, are capable
of retarding S-phase progression, suggesting that a com-
mon mechanism may exist for enhancing cytotoxicities
against tumor cells by flavopiridol [20-22]. Our flow cyto-
metric data showed here that AdHTVP2G5-rev-casp3
caused a significant increase in the percentage of OVCAR3
cells in the S-phase in vitro. We further showed that
AdHTVP2G5-rev-casp3 sensitized OVCAR3 cells to
flavopiridol with an apoptotic rate of 71.9% compared
with no apparent apoptotic activities in OVCAR3 cells
treated with either agent alone. We additionally found
that the synergism between AdHTVP2G5-rev-casp3
and flavopiridol was sequence dependent and time
dependent. It required that rev-caspase-3 precede
flavopiridol by 72 hs. Exposure to flavopiridol preceding or
concomitantly with rev-caspase-3 did not enhance cell
death.
We have checked the levels of ALT and AST for their
toxicity, and found that the acute toxicity by flavopiridol
(10 mg/kg) alone was significantly increased after 1 days,
much higher than that of the combination of flavopiridol
(5 mg/kg) and AdHTVP2G5-rev-casp3 (2.5 × 108). 10 mg/kg
is the maximum tolerated dose(MTD) of flavopiridol
in vivo, and this dose of flavopiridol can induce high
toxicity levels in acute phase. But the combination of
half of the MTD of flavopiridol (5 mg/kg) and low doseof AdHTVP2G5-rev-casp3 (7 × 108 TCID50/mouse) induce
much lower ALT and AST level than that in mice receiving
10 mg/kg flavopiridol alone (88.1 ± 7.8 vs. 289.3 ± 15.7,
91.5 ± 9.4 vs. 548.1 ± 42.9,respectively, P < 0.01 in both).
This result showed that the combination of low dose
flavopiridol and AdHTVP2G5-rev-casp3 can reduce the
toxicity level, while maintain the synergism against
xenograft growth in vivo.
In conclusion, we generated AdHTVP2G5-rev-casp3
and used it in sequential treatment with flavopiridol in
OVCAR3 cells in vitro and in mouse xenograft model.
We demonstrated that the sequential combination
regimen exhibited synergistic cytotoxic activities against
OVCAR3 cells in vitro and significantly inhibited tumor
growth in mice and markedly extended the survival of
tumor-bearing mice. Our findings indicate that the sequen-
tial combination regimen should be further explored as a
potentially clinically useful treatment.
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